Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study.

This study tested whether the plasma level of total homocysteine (tHcy) was predictive of obstructive coronary artery disease (CAD) and clinical outcome in patients undergoing coronary angiographic (CAG) study. From September 2002 to October 2004, 1,305 consecutive patients with angina pectoris undergoing CAG study were consecutively enrolled. Blood samples were prospectively collected to assess the plasma level of tHcy from each patient before catheterization. Of these 1305 patients, 676 (51.8%) had multivessel disease (group 1), 367 (28.1%) had single-vessel disease (group 2), and 262 (20.1%) had normal coronary artery or insignificant coronary artery disease (group 3). The plasma level of tHcy was notably higher in group 1 than in groups 2 and 3 (11.6 ± 4.4 versus 10.9 ± 4.0 versus 10.4 ± 3.8, P < 0.001). Univariate binary logistic regression analysis demonstrated that the plasma tHcy level was strongly associated with multiple-vessel disease (MVD) (defined as ≥ 2 vessel disease) (P < 0.001). Multivariate binary logistic regression analysis showed that tHcy level, fasting blood sugar, diabetes mellitus, and age were significantly and independently predictive of MVD (all P < 0.03). Univariate Cox regression analysis demonstrated that tHcy level was predictive of long-term mortality (P = 0.042). However, the tHcy level was not an independent predictor of long-term mortality on multivariate Cox regression analysis (P > 0.05). The results of our study support the hypothesis that tHcy level is an independent predictor of MVD in patients with chest pain undergoing CAG study. Conversely, our study did not support the tHcy level as an independent predictor of long-term mortality in this clinical setting.

[1]  J. Genest C-reactive protein: risk factor, biomarker and/or therapeutic target? , 2010, The Canadian journal of cardiology.

[2]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[3]  B. Nagalla,et al.  Gender-Related Differences in the Relationship between Plasma Homocysteine, Anthropometric and Conventional Biochemical Coronary Heart Disease Risk Factors in Middle-Aged Indians , 2009, Annals of Nutrition and Metabolism.

[4]  C. Stefanadis,et al.  Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. , 2008, European heart journal.

[5]  A. Hamsten,et al.  Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. , 2006, Atherosclerosis.

[6]  Cheuk-Kwan Sun,et al.  Strong correlation between serum levels of inflammatory mediators and their distribution in infarct-related coronary artery. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[7]  H. Yip,et al.  Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. , 2005, International heart journal.

[8]  D. Levy,et al.  Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death From 1950 to 1999: The Framingham Heart Study , 2004, Circulation.

[9]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[10]  E. Vittinghoff,et al.  Risk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study , 2003, Annals of Internal Medicine.

[11]  S. Vasikaran,et al.  Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. , 2002, Clinical science.

[12]  O. Hess,et al.  Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. , 2002, European heart journal.

[13]  R. Virmani,et al.  Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies , 2002, Circulation.

[14]  K. Bushara,et al.  Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels , 2002, Clinical cardiology.

[15]  F. Corrales,et al.  Hyperhomocysteinemia in Liver Cirrhosis: Mechanisms and Role in Vascular and Hepatic Fibrosis , 2001, Hypertension.

[16]  A. Reunanen,et al.  Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? , 2001, Archives of internal medicine.

[17]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[18]  B. Horne,et al.  Plasma Homocysteine Predicts Mortality Independently of Traditional Risk Factors and C-Reactive Protein in Patients With Angiographically Defined Coronary Artery Disease , 2000, Circulation.

[19]  Medina,et al.  Homocysteine: an emergent cardiovascular risk factor? , 2000, European journal of clinical investigation.

[20]  I. Rosenberg,et al.  Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem , 1999, Annals of Internal Medicine.

[21]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[22]  R. D'Agostino,et al.  Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. , 1999, Archives of internal medicine.

[23]  S. Yusuf,et al.  Emerging epidemic of cardiovascular disease in developing countries. , 1999, Circulation.

[24]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[25]  J. Danesh,et al.  Plasma Homocysteine and Coronary Heart Disease: Systematic Review of Published Epidemiological Studies , 1998, Journal of cardiovascular risk.

[26]  A. Folsom,et al.  Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. , 1998, Circulation.

[27]  P. McBride,et al.  Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. , 1998, Archives of internal medicine.

[28]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[29]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[30]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[31]  L. Coupal,et al.  Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.

[32]  P. Ueland,et al.  Total homocysteine in plasma or serum: methods and clinical applications. , 1993, Clinical chemistry.

[33]  J. Hermiller,et al.  Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. , 1992, Catheterization and cardiovascular diagnosis.

[34]  P. Ueland,et al.  Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. , 1989, The Journal of laboratory and clinical medicine.

[35]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[36]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.

[37]  L. Bouter,et al.  Follow-Up of the Hoorn Study Hyperhomocysteinemia Increases Risk of Death , Especially in Type 2 Diabetes : 5-Year , 2000 .

[38]  Elga,et al.  PLASMA HOMOCYSTEINE LEVELS AND MORTALITY IN PATIENTS WITH CORONARY ARTERY DISEASE , 2000 .